News

According to the companies, the tool is affordable, portable, scalable, and intentionally designed to train surgeons in low- and middle-income countries, home to 9 out of 10 people with vision loss due to the difficulty of accessing eye care. The VR tool is being unveiled at the American Society of Cataract and Refractive Surgery Annual Meeting in Boston.

Authors reported that increasing the number of intense pulsed light (IPL) sessions is beneficial for patients with moderate-to-severe meibomian gland dysfunction (MGD) to increase the response rate of treatment.

The technology uses a superelastic, memory-shaped nitinol guide that facilitates up to 360-degree guided circumferential removal of the trabecular meshwork.

The investigators conducted a multicenter, prospective, open-label, phase 4 study in which they evaluated the patients’ and investigators’ impressions of the drug.

Authors looked at 6 unexpected cases of endophthalmitis after cataract extraction during 1 day of cataract surgeries.

George O. Waring IV, MD, FACS, provides an overview of his presentation at ASCRS 2024, highlighting outcomes for the safety and effectiveness of LASIK performed using an updated laser ablation algorithm for the correction of myopia and myopic astigmatism.

A recent study showed that adjunctive fragmentation pre-treatment of the crystalline lens using the miLoop showed improved lensectomy time and fluidic efficiency

Neda Nikpoor, MD, sat down to discuss her presentation on the single-site study on the effectiveness of a sterile model with two ALLYs, in two operating rooms against a model with only one laser for two rooms at this year's ASCRS meeting held in Boston, Massachusetts.

Sean Hanlon, CEO of CoFi, a payment software company, talks about the company's recent integration with CareCredit.

Ula Jurkunas, MD, sat down to discuss her presentation on the management of anterior corneal disease at this year's ASCRS meeting held in Boston, Massachusetts.

Roger Kennedy, director of marketing at BioTissue sat down to discuss the new products the company will be unveiling at this year's ASCRS meeting held in Boston, Massachusetts.

Jennifer Loh, MD, sat down to discuss her presentation on major eye issues that can interfere with refractive cataract surgery, specifically dry eye disease, at this year's ASCRS meeting held in Boston, Massachusetts.

Spencer will formally receive his award during the 2024 ASCRS Annual meeting, being held April 5 to 8, as part of its 50th anniversary celebration.

Diabetic macular edema is often treated with dexamethasone intravitreal implant, and bevacizumab. While they both treat the same disease, they work in different ways.

Zeiss has secured regulatory approvals to acquire DORC, and the companies will now shift their focus to integration implementation.

Thompson will assume the presidency of the ASCRS, which is celebrating its 50th anniversary in 2024. The organization kicks off its 2024 annual meeting Friday at Boston Convention and Exhibition Center in Boston.

The company’s Lacrifill canalicular gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Researchers have linked ZIKV to ocular deformities in infants that include retinal lesions, microphthalmia, hemorrhagic retinopathy, retinal pigmented epithelium mottling, optic neuritis and hypoplasia of the optic nerve.

Zachary Robertson, MD, a retina specialist at the University of Texas Southwestern Medical Center talked with David Hutton of Ophthalmology Times about the upcoming solar eclipse and what potential damages the event could cause on the retina.

The 2 organizations to receive initial gifts will be Sight for Life and Eye Corps.

NEPTUNE represents the seventh positive Phase 2 study for brepocitinib with more than 1400 subjects and patients treated with brepocitinib in clinical trials. Brepocitinib was generally safe and well-tolerated in the study; no new safety and tolerability signals were identified.

Extended treatment intervals with bevacizumab preserved vision of many patients with high baseline vision.

The company announced it will share clinical data at Eyecelerator and the American Society of Cataract and Refractive Surgery 2024 Annual Meeting in Boston.

The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.

According to the company, EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

One year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths.

Phentolamine ophthalmic solution 0.75% is a preservative-free, stable eye drop, which blocks the α1 receptor within the iris dilator muscle without affecting the ciliary muscle.